Navigation Links
New Prostate Cancer Drug May Hold Promise
Date:4/7/2009

Researchers apply for large-scale testing after 'very promising' early results,,

TUESDAY, April 7 (HealthDay News) -- A new drug with a radically different way of attacking prostate cancer has done well in an initial trial and is ready for larger-scale testing, researchers report.

One standard treatment for the malignancy is to inhibit the activity of androgens, male hormones such as testosterone that help drive tumor growth. Existing anti-androgens try to "shut down the factory" that produces the hormones, but the new drug blocks the receptors for those androgens on the tumor cells, said Dr. Howard I. Scher, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York City and co-author of a report to be published online by the journal Science.

"There is a lot of interest in the drug, because the preliminary results are very promising," Scher said.

The report in the journal describes the results of the treatment of 30 men with advanced prostate cancer that was not responding to conventional anti-androgen therapy. After treatment with the drug, there were "sustained declines" in blood levels of prostate specific antigen, a biomarker of tumor growth, in 13 of the 30, or 43 percent, which the report called a "promising" result.

The researchers now have data on 114 men given the drug, Scher said. "It showed not only declines in PSA but also regression of the tumor on scans and also that circulating tumor cell counts, another measure of treatment, converted from unfavorable to favorable in a considerable percentage of patients," he said.

Based on those results, Scher said, an application for a large-scale trial has been submitted to the U.S. Food and Drug Administration by Medivation Inc., a California-based biopharmaceutical company that has licensed the drug, now called MDV3100. The hope is that the trial will lead to FDA approval of the drug for clinical use.

The trial would be international in scope, he said, but the length and size have not been determined.

MDV3100 came out of research done at the University of California, Los Angeles, by Dr. Charles L. Sawyers, a cancer biologist who now is chairman of the human oncology and pathogenesis program at Sloan-Kettering.

"My laboratory was studying why men develop resistance to current anti-androgen drugs," Sawyers said. "We found that resistant tumors have higher levels of androgen receptors. What we showed was that cells, by making more of these receptors, can escape those drugs. Based on that, we developed a cell line that made higher levels of receptors and used that as a screen for compounds that could block the receptors."

Sawyers did the research in collaboration with a group led by Michael Jung, a chemist at UCLA. "We had some ideas about what chemical structures we might need to get such a result," Sawyers said. "His group synthesized a set of compounds, my group screened them, and over the months, we learned what to do. There were a number of chemicals known to bind to a receptor with different affinities, and we made derivatives of them."

That work produced more than one effective receptor blocker. MDV3100 was selected as the most promising.

Though the immediate goal is to get FDA approval for use of the drug in men whose prostate cancers do not respond to existing anti-androgen therapy, the ultimate hope is that it could be used for first-line therapy, Scher and Sawyers said.

"That is a typical scenario," Sawyers said. "First you test it in late-stage patients. If it is effective there, you would want to move it to front-line therapy."

About half of all prostate cancers have the overgrowth of androgen receptors that MDV3100 is designed to attack, Scher noted.

Side effects do not appear to be a problem, Sawyers said. "At high doses, fatigue has been a problem in some men -- higher doses than are needed to get benefit," he said.

More information

The U.S. National Cancer Institute has more on prostate cancer.



SOURCES: Howard I. Scher, M.D., chief, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, New York City; Charles L. Sawyers, M.D., chairman, human oncology and pathogenesis program, Memorial Sloan-Kettering Cancer Center, New York City; April 9, 2009, Science, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Prostate Cancer Drug May Hold Promise
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as ... production of the series is on hiking in American. Viewers can reconnect with America ... great benefits of hiking. , Many consumers have looked for an inventive new place ...
(Date:5/26/2017)... ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of ... Cross” is the creation of published authors, Bob and Margaret Massey. Bob Massey is ... is "panther quick and leather tough." His love for others is apparent in all ...
(Date:5/26/2017)... ... ... Jack: Against All Odds”: the story of Coach Cactus Jack and the impact he ... creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and pharmacy ... Walter and Jane have three adult children and a granddaughter. Walter and ...
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... California (PRWEB) , ... May 24, 2017 , ... ... through innovative medical image management and interpretation, has received U.S. Food and Drug ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical image ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/9/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... has earned a spot on Forbes, "America,s ... ranked among 500 U.S. employers as well as in ... Services. The annual Forbes rankings ... of over 30,000 employees across 25 industries. The survey ...
Breaking Medicine Technology: